Reality Check On UK Production Capacity For COVID-19 Treatments
Debate Shifts From Treatments To Scalability, Manufacturing Capacity, And Delivery
In the first of a two-part series of articles on the UK COVID-19 Therapeutics Task Force, the Pink Sheet reports on how task force members are examining the role of therapeutics in tackling the pandemic and why the UK’s manufacturing capability needs to be strengthened so it can meet future demand. The second article will cover the work of the task force and how it is structured to identify and advance promising coronavirus treatments.
